About Afferent Pharmaceuticals
Afferent Pharmaceuticals is a company based in San Mateo (United States) founded in 2009 was acquired by Merck in June 2016. Afferent Pharmaceuticals has raised $78.15 million across 3 funding rounds from investors including Merck, Fidelity Investments and New Leaf Venture Partners. The company has 5 employees as of December 31, 2015. Afferent Pharmaceuticals offers products and services including Medicines, Vaccines, and Patient Assistance Programs. Afferent Pharmaceuticals operates in a competitive market with competitors including Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
- Headquarter San Mateo, United States
- Employees 5 as on 31 Dec, 2015
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Afferent Pharmaceuticals, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Afferent Pharmaceuticals
Afferent Pharmaceuticals offers a comprehensive portfolio of products and services, including Medicines, Vaccines, and Patient Assistance Programs.
Treatments for diseases like oncology and infections
Preventive solutions against infectious diseases
Financial aid for accessing medications
Funding Insights of Afferent Pharmaceuticals
Afferent Pharmaceuticals has successfully raised a total of $78.15M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $55 million completed in July 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Afferent Pharmaceuticals
Afferent Pharmaceuticals has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Fidelity Investments and New Leaf Venture Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Stage-agnostic investments in US life sciences are managed.
|
Locked | Locked | Locked | |
|
Venture capital funding is provided to early-stage life science companies.
|
Locked | Locked | Locked | |
|
Life science & tech focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Afferent Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Afferent Pharmaceuticals
Investment portfolio details for Afferent Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Afferent Pharmaceuticals
Detailed financials for Afferent Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Afferent Pharmaceuticals Comparisons
Peer comparison for Afferent Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Afferent Pharmaceuticals
Afferent Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Flexion Therapeutics, Eliem Therapeutics, Zogenix, Heron Therapeutics and Ethypharm, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of therapies for the treatment of musculoskeletal disorders
|
|
| Locked | Locked | Locked |
Develops antibody-based treatments for autoimmune and inflammatory disorders.
|
|
| Locked | Locked | Locked |
Drug delivery systems for CNS disorders and pain are developed.
|
|
| Locked | Locked | Locked |
Reformulated injectables for chemotherapy side effects and pain are developed.
|
|
| Locked | Locked | Locked |
Therapies for pain and addiction treatment are developed.
|
|
| Locked | Locked | Locked |
Therapeutics for pain management are developed with abuse-deterrent designs.
|
Detailed competitors of Afferent Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Afferent Pharmaceuticals
Complete news archive for Afferent Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Afferent Pharmaceuticals
Afferent Pharmaceuticals was founded in 2009.
Afferent Pharmaceuticals is headquartered in San Mateo, United States. It is registered at San Mateo, California, United States.
Afferent Pharmaceuticals is a funded company, having raised a total of $78.15M across 3 funding rounds to date.
As of Dec 31, 2015, the latest employee count at Afferent Pharmaceuticals is 5.
Afferent Pharmaceuticals was founded in 2009 as a clinical-stage biopharmaceutical company based in San Mateo, United States. Small molecule compounds targeting P2X3 receptors are developed for chronic pain, respiratory, and urological conditions. The pipeline includes AF-219, applied to osteoarthritis pain, treatment-refractory chronic cough, and interstitial cystitisbladder pain syndrome, along with AF-220 as a second-generation P2X3 antagonist.
Afferent Pharmaceuticals's top competitors include Flexion Therapeutics, Cara Therapeutics and Satsuma Pharmaceuticals.
Afferent Pharmaceuticals offers Medicines, Vaccines, and Patient Assistance Programs.
Afferent Pharmaceuticals has 10 investors. Key investors include Merck, Fidelity Investments, New Leaf Venture Partners, Tekla Capital Management, and Jennison Associates.